Immunogenicity and Safety According to Immunosuppressive Drugs and Different COVID-19 Vaccine Platforms in Immune-Mediated Disease: Data from SAFER Cohort
All platforms were safe and induced an increase in IgG-S antibodies. COVID-19 pre-exposure and BNT162b2 booster regimens were predictors of higher humoral immune responses, which is relevant in immunosuppressed populations. Immunosuppressants (mainly rituximab) predicted the lowest antibodies.
Authors
- Viviane Angelina de Souza (ORCID: https://orcid.org/0000-0001-6386-3776)
- Erika Biegelmeyer (ORCID: https://orcid.org/0000-0003-4978-040X)
- Vanessa Hax (ORCID: https://orcid.org/0000-0003-3240-7174)
- Natália Sarzi Sartori (ORCID: https://orcid.org/0000-0002-4316-0771)
- Renata Henriques de Azevedo
- Emília Inoue Sato (ORCID: https://orcid.org/0000-0001-8540-014X)
- Gilda Aparecida Ferreira (ORCID: https://orcid.org/0000-0002-1352-7261)
- Olindo Assis Martins‐Filho (ORCID: https://orcid.org/0000-0002-5494-4889)
- Valderílio Feijó Azevedo (ORCID: https://orcid.org/0000-0002-2346-388X)
- Valéria Valim (ORCID: https://orcid.org/0000-0002-0625-1308)
- Andréa Teixeira‐Carvalho (ORCID: https://orcid.org/0000-0003-2814-5183)
- Vítor Alves Cruz (ORCID: https://orcid.org/0000-0002-3073-2929)
- Ketty Lysie Libardi Lira Machado (ORCID: https://orcid.org/0000-0003-2545-6795)
- Isac Ribeiro Moulaz (ORCID: https://orcid.org/0000-0003-1014-9581)
- Vanessa de Oliveira Magalhães
- Camila Maria Paiva França Telles (ORCID: https://orcid.org/0000-0001-9168-9816)
- Gecilmara Salviato Pileggi (ORCID: https://orcid.org/0000-0003-0054-7754)
- Priscila Dias Cardoso Ribeiro (ORCID: https://orcid.org/0000-0003-2598-810X)
- Odirlei André Monticielo (ORCID: https://orcid.org/0000-0003-0720-2097)
- José Geraldo Mill (ORCID: https://orcid.org/0000-0002-0987-368X)
- Flávia Maria Matos Melo Campos Peixoto
- Ana Paula Neves Burian (ORCID: https://orcid.org/0000-0002-5056-5523)
- Marcelo M. Pinheiro (ORCID: https://orcid.org/0000-0002-1896-8322)
- Sandra Lúcia Euzébio Ribeiro (ORCID: https://orcid.org/0000-0002-4777-8659)
- Rodrigo Poubel Vieira de Rezende (ORCID: https://orcid.org/0000-0002-1623-259X)
- Ana Karla Guedes de Melo (ORCID: https://orcid.org/0000-0002-4809-9965)
- Juliana Bühring (ORCID: https://orcid.org/0000-0002-9944-7229)
- Ricardo Machado Xavier (ORCID: https://orcid.org/0000-0001-6570-4533)
- Rejane Maria Rodrigues de Abreu Vieira (ORCID: https://orcid.org/0000-0003-4475-6064)
- Kátia Lino (ORCID: https://orcid.org/0000-0002-6134-8495)
- Edgard Torres dos Reis Neto
- Karina Rosemarie Lallemand Tapia (ORCID: https://orcid.org/0000-0003-2033-9557)
- Lunara Baptista Ferreira
- Anna Carolina Simões Moulin
Institutions
- Universidade Federal de Juiz de Fora (BR)
- Universidade Federal de Minas Gerais (BR)
- Universidade Federal do Rio Grande do Sul (BR)
- Universidade Federal Fluminense (BR)
- Universidade Federal da Paraíba (BR)
- Universidade de Fortaleza (BR)
- Hospital de Clínicas de Porto Alegre (BR)
- Hospital Universitário Lauro Wanderley (BR)
- Secretaria da Saúde (BR)
- Hospital Geral de Fortaleza (BR)
- Universidade Federal do Espírito Santo (BR)
- Fundação Oswaldo Cruz (BR)
- Universidade Federal do Amazonas (BR)
- Universidade Federal de Goiás (BR)
- Universidade Federal de São Paulo (BR)
Publication Details
- Journal
- Vaccines
- Published
- 2024-12-03
- DOI
- https://doi.org/10.3390/vaccines12121367
- Citations
- 4
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.56
Funders
- Ministério da Saúde
- Fundação Oswaldo Cruz